ArticleThe Journal of general virology2026
Serological response to feline coronavirus in the UK domestic cat population.
Article in The Journal of general virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Feline coronavirus (FCoV) is a ubiquitous virus of cats, with highly variable seroprevalence, ranging between 4 and 95% worldwide in the domestic cat population. It is the causative agent of feline infectious peritonitis (FIP), a disease which, prior to the recent introduction of effective antiviral drug treatments, was invariably fatal. The recent outbreak of FIP, originating in Cyprus and caused by the novel recombinant FCoV-23, highlighted the need to increase understanding of the serological response to FCoV. This study aimed to characterize the serological response to the virus and to assess cross-neutralization of type II FCoV subtypes as well as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In serum samples of 1117 UK cats collected between 2020 and 2023, we detected an FCoV-II neutralizing antibody (nAb) seroprevalence of 13.6% and an overall seroprevalence of 59.5%; commonly cited risk factors (sex, age and breed) did not significantly impact the nAb seroprevalence nor nAb titre against FCoV-II. Antibodies against subtypes FIPV-79-1146 and FIPV-DF-2 were found to be cross-reactive and additionally neutralized both isoforms of FCoV-23. In contrast, no cross-neutralization was observed against SARS-CoV-2. Overall, these results highlight that although FCoV infection offers effective cross-protection between FCoV strains and subtypes, this does not extend to betacoronaviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.